NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Seagen Inc.
J-Pharma Co., Ltd.
Merck Sharp & Dohme LLC
Lisata Therapeutics, Inc.
Leaf Vertical Inc.